Adding bevacizumab to initial treatment for glioblastoma did not improve overall patient survival or progression-free survival, according to results of a randomized phase III trial.
The use of tailored, web-based videos delivering educational information before an oncologist visit can significantly improve knowledge and reduce attitudinal barriers that impact enrollment in clinical trials, according to one new study.
A clinical trial has shown that patients and their physicians are eager to jump into next-era cancer care, which is analysis of a patient's tumor to find and target genetic mutations that drive the cancer. The results of the study, CUSTOM, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology.
Among women with estrogen-receptor positive breast cancer, late recurrence was best predicted by the clinical treatment score. Significant prognostic value was added by the PAM50 risk of recurrence score and by the Breast Cancer Index score, according to a study comparing five scores that was presented at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.
A new class of drugs targeting the genetic material of skin cancer has been successfully tested in humans for the first time. This opens the way to new treatments for a range of conditions from skin cancers to eye diseases.
New light was shed on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC) by data from clinical trials presented at the International Liver Congress 2013 in Amsterdam, the Netherlands.
Orally administered rigosertib was found to be well-tolerated in patients with advanced solid tumors in a phase 1 trial. Rigosertib is a dual kinase inhibitor, and this trial is the first to study its orally administered form in solid tumors.
A new class of tumor-fighting drugs that use RNA interference were studied for their safety and preliminary efficacy.
Funding source, number of participants, and journal impact factor all affect time to publication.
The median age of patients diagnosed with advanced NSCLC has steadily increased over recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials.
A phase II clinical trial provides the first evidence of a relatively high response rate in patients with low-grade serous ovarian cancer receiving the drug selumetinib.
Bevacizumab plus chemotherapy improved survival in women with advanced, recurrent, or persistent cervical cancer, according to interim findings.
A new drug, calmangafodipir, protects against the side effects of cancer treatments while strengthening the effects on the tumor. An international drug evaluation is now beginning with a larger group of patients.
A multicenter phase III clinical trial has demonstrated that nab-paclitaxel (Abraxane) plus gemcitabine extends the survival of late-stage pancreatic cancer patients compared with standard treatment.
A third of all trials that failed to show a statistically significant benefit for the treatment under investigation focused on other, less important outcomes in order to put a positive spin on the results, according to a recent study.
A new experimental drug therapy has been developed to target activated B-cell diffuse large B-cell lymphoma.
Interim results confirmed the "unprecedented" single-agent activity of ibrutinib in relapsed or refractory mantle cell lymphoma.
Older patients may not respond as well as younger persons to conventional therapies for chronic lymphocytic leukemia, a new study indicates.
A new immunomodulatory drug under FDA review significantly increased survival in persons with multiple myeloma, including older patients.
The FDA has expanded the indication for abiraterone acetate (Zytiga tablets) to combat metastatic castration-resistant prostate cancer.
The final data from a phase II study confirmed the high degree of activity of quizartinib in persons with acute myeloid leukemia.
Early results of a trial to treat leukemia with WT1 DNA vaccine have shown robust vaccine-specific antibody responses in all vaccinated patients evaluated to date.
About two-thirds of patients treated with cabozantinib had improvements on their bone scans, with 12% seeing complete resolution on uptake on bone scans.
Ibrutinib, which targets the Bruton's tyrosine kinase to combat chronic lymphocytic leukemia, showed promising results in two phase II studies.
A drug used for metastatic breast cancer after several previous treatments may improve survival when administered earlier in the disease course.
Vorinostat, already used in lymphoma, reduces the risk of graft-versus-host disease after allogeneic hematopoietic stem-cell transplantation.
Newly approved for prostate cancer, enzalutamide may be useful as a therapeutic agent in breast cancer that evades other treatments.
The American Society of Clinical Oncology has released a nearly 100-page report detailing the year's most significant developments in cancer.
Use of the oral antidiabetes drug metformin improved survival in women with ovarian cancer, according to the findings of a retrospective case-control study.
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|